New drugs could reach market sooner as govt halves trial review timeline

The Indian government is shaking up the pharmaceutical sector by slashing the review period for manufacturing applications for new drugs to 45 days. Now, manufacturers can initiate clinical trials or bioequivalence studies with just a prior notification to the regulators, ditching the old requirement for express permission.